Noninvasive Prenatal Testing Market Set for Explosive Growth
|
By HospiMedica International staff writers Posted on 21 Jan 2014 |
|
The global noninvasive prenatal testing (NIPT) market is expected to grow more than ten-fold in the next five years. These are the latest findings of Transparency Market Research (Albany, NY, USA), a global information and research provider.
NIPT, the noninvasive genetic screening test for common chromosomal abnormalities (trisomy 21, trisomy 18, trisomy 13, monosomy X, etc.) can detect the presence of abnormalities in fetuses of pregnant women as early as 9–10 weeks of gestation, with some of the most commonly detected chromosomal aneuploidies include Down syndrome, Edwards syndrome, Patau syndrome, and monosomy X. The market is also evolving rapidly due the advantages it offers over conventional prenatal screening and diagnostic methods such as maternal serum screening, nuchal translucency (NT) scan, amniocentesis, and chorionic villus sampling (CVS). These advantages include safety, accuracy, and no risk of miscarriage.
MaterniT21 PLUS, verifi, Harmony, Panorama, NIFTY, PrenaTest, and BambniTest are currently the commercially available NIPTs, all based on the direct analysis of cell-free fetal DNA in the maternal blood. In 2012, MaterniT21 (a proprietary product of Sequenom) accounted for the largest share (36.6%) of the market in terms of revenue, owing to the fact that it was the first mover in the market place. During the forecast period 2013 to 2019, it is likely to lose some of its share due to increasing market penetration by other, aforementioned NIPTs such as Panorama and verify.
Almost every company in this market is adopting the same business model of marketing their tests via alliances with hospitals, diagnostic laboratories, and physician offices. The increasing penetration by test developers in European, Asia-Pacific, and Middle East countries indicates promising growth in the near future. Sequenom (San Diego, CA, USA), Verinata Health (Redwood City, CA, USA), Ariosa Diagnostics, and Natera (San Carols, CA, USA), are the leading companies engaged in providing noninvasive prenatal tests worldwide.
The global NIPT market was valued at USD 220 million in 2012 and is expected to grow at a compound annual growth rate (CAGR) of 37.6% from 2013 to 2019, to reach an estimated value of USD 3.62 billion by 2019. Geographically, North America was the largest regional market in 2012, with a market share of 64.5% of the total revenue generated globally, followed by Europe.
Related Links:
Transparency Market Research
Sequenom
Verinata Health
NIPT, the noninvasive genetic screening test for common chromosomal abnormalities (trisomy 21, trisomy 18, trisomy 13, monosomy X, etc.) can detect the presence of abnormalities in fetuses of pregnant women as early as 9–10 weeks of gestation, with some of the most commonly detected chromosomal aneuploidies include Down syndrome, Edwards syndrome, Patau syndrome, and monosomy X. The market is also evolving rapidly due the advantages it offers over conventional prenatal screening and diagnostic methods such as maternal serum screening, nuchal translucency (NT) scan, amniocentesis, and chorionic villus sampling (CVS). These advantages include safety, accuracy, and no risk of miscarriage.
MaterniT21 PLUS, verifi, Harmony, Panorama, NIFTY, PrenaTest, and BambniTest are currently the commercially available NIPTs, all based on the direct analysis of cell-free fetal DNA in the maternal blood. In 2012, MaterniT21 (a proprietary product of Sequenom) accounted for the largest share (36.6%) of the market in terms of revenue, owing to the fact that it was the first mover in the market place. During the forecast period 2013 to 2019, it is likely to lose some of its share due to increasing market penetration by other, aforementioned NIPTs such as Panorama and verify.
Almost every company in this market is adopting the same business model of marketing their tests via alliances with hospitals, diagnostic laboratories, and physician offices. The increasing penetration by test developers in European, Asia-Pacific, and Middle East countries indicates promising growth in the near future. Sequenom (San Diego, CA, USA), Verinata Health (Redwood City, CA, USA), Ariosa Diagnostics, and Natera (San Carols, CA, USA), are the leading companies engaged in providing noninvasive prenatal tests worldwide.
The global NIPT market was valued at USD 220 million in 2012 and is expected to grow at a compound annual growth rate (CAGR) of 37.6% from 2013 to 2019, to reach an estimated value of USD 3.62 billion by 2019. Geographically, North America was the largest regional market in 2012, with a market share of 64.5% of the total revenue generated globally, followed by Europe.
Related Links:
Transparency Market Research
Sequenom
Verinata Health
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Fetal Monitor
BT-380
Multi-Chamber Washer-Disinfector
WD 390
Latest Business News
- Smartphone-Integrated Epinephrine Auto-Injector Concept Wins Red Dot Design Award
- Partnership Advances AI Tool for Predicting Malignant Cerebral Edema
- First U.S. Commercial Cases Demonstrate New Approach to Transseptal Access
- Philips and Imricor Collaboration Advances MRI-Guided Cardiac Procedures
- FDA Approval Clears Path for BCI Integration with Personal Computing Devices
- Abbott LAA Occluder Gains CE Mark for AFib Stroke Risk Reduction
- Smart Hospital Market Set for Strong Growth as Digital Healthcare Adoption Accelerates
- FDA Seeks Feedback on Regulating Generative AI Medical Devices
- Teledyne to Acquire Varex Imaging in $1.1 Billion Deal
- MIMEDX to Add Sanara MedTech’s Regenerative Technologies Through $350 Million Deal
- AI Software Combines Nodule Detection and Diagnosis for Lung Cancer Screening
- AI Care Platform Adds Quantitative MRI Analysis for Multiple Sclerosis
- Danaher Completes Acquisition of Masimo to Expand Patient Monitoring Capabilities
- Endologix Adds FDA-Cleared Peripheral Thrombectomy System
- Artivion Adds FDA-Approved NEXUS System to Aortic Arch Portfolio
- Olympus Partnership Aims to Expand Access to Robot-Assisted Endoscopic Therapy
Channels
Artificial Intelligence
view channel
AI Framework Aims to Turn Medical Care from Reactive to Preventive
Health systems face rising burdens from aging populations, chronic disease, and workforce shortages. Medical artificial intelligence (AI) remains concentrated in diagnosis and decision support, leaving... Read more
AI Model Predicts Indwelling Catheter Use After Spinal Cord Injury
Patients with early-stage spinal cord injury and neurogenic bladder often face uncertain trajectories in urinary catheter management. Clinicians need tools to anticipate conversion to indwelling catheters... Read more
Critical Care
view channel
Patch-Based Therapy Promotes Myelin Repair in Multiple Sclerosis
Multiple sclerosis (MS) is a chronic autoimmune disease that damages the myelin sheath in the central nervous system, leading to progressive disability. After inflammatory attacks, remyelination is often... Read more
Remote Cardiac Device Monitoring System Shows Safety and Cost Benefits
Regular in-clinic follow-up for patients with cardiac implantable electronic devices, including pacemakers and implantable cardioverter defibrillators, is resource intensive. As device use rises with aging... Read more
Surgical Techniques
view channel
Nanobone Material Activates Natural Repair Signals to Regrow Bone
Cleft lip and palate is a birth defect that affects about 1 in 700 children and occurs when parts of the upper lip or roof of the mouth do not fully fuse during pregnancy. Repairing the resulting jawbone... Read more
First Robotic Dual Liver-Kidney Transplant Expands Minimally Invasive Transplant Surgery
Patients with end-stage liver disease often develop renal failure, creating the need for simultaneous liver-kidney transplantation. Traditional open dual-organ transplantation requires large incisions... Read more
Patient Care
view channel
Weighted Blankets Reduce Anxiety in Hospitalized Adults
Anxiety is common among hospitalized adults and can impair recovery, disrupt sleep, and worsen mental health. Although clinicians often use nonpharmacologic strategies, bedside options that act quickly... Read more
Multicenter Study Quantifies Delays in Care for Emergency Department Boarders
Emergency department (ED) boarding—the practice of keeping admitted patients in the ED while awaiting an inpatient bed—creates hazardous delays in definitive care. Prolonged transitions expose older and... Read more
Medical Imaging
view channel
Targeted PET/MRI Improves Detection and Preoperative Mapping of Endometriosis
Endometriosis is a chronic inflammatory condition in which endometrial-like tissue grows outside the uterus, causing pelvic pain, infertility, and reduced quality of life. Conventional imaging can underestimate... Read more
AI-Guided Ultrasound Enables Nonexpert Screening for Aortic Stenosis
Aortic stenosis is a narrowing of the aortic valve that can progress silently until advanced disease. Comprehensive echocardiography is the diagnostic standard, but it requires specialized equipment and... Read more
Health IT
view channel
Nurse-Coordinated Care Model Improves Heart Failure Outcomes
Heart failure imposes heavy mortality, morbidity, and cost burdens worldwide, yet proven therapies remain underused in routine practice. This inadequate uptake contributes to preventable hospitalizations... Read more
Imaging Tool Quantifies Calcinosis Cutis Volume to Monitor Treatment
Calcinosis cutis involves calcium deposits in the skin or soft tissues that can develop anywhere in the body, causing pain, impaired mobility, and disability. Lesions along the spine or buttocks can make... Read more
Point of Care
view channel
Microneedle Patch Enables At-Home Monitoring of Acute Kidney Injury
Kidney disease is often silent in its early stages, making timely detection difficult outside clinical settings. Early biomarkers such as neutrophil gelatinase–associated lipocalin can require blood draws... Read more
